Diagnostic, prognostic and therapeutic role of CD30 in lymphoma

Pierce, John; Mehta, Amitkumar

doi:10.1080/17474086.2017.1270202

Cited by 50 publications

(43 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…68,69 Other lymphoproliferative disorders, such as DLBCL, primary mediastinal B-cell lymphoma (PMBCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides (MF), Sézary syndrome (SS) and adult T-cell leukemia/lymphoma (ATLL), can also express CD30 to various degrees. [70][71][72] A chimeric mAb SGN-30, consisting of the variable region of an anti-CD30 murine mAb with human gamma 1 heavy chain and kappa light chain constant regions, promotes growth arrest and DNA fragmentation in vitro and exhibits antitumor activity in HL models. 73 In a phase 2 study of relapsed or refractory HL or ALCL, SGN-30 showed only a modest effect in ALCL (2 CR and 5 PR in 41 ALCL patients).…”

Section: Cd30mentioning

confidence: 99%

Advances in targeted therapy for malignant lymphoma

Wang

Qin

Huo

et al. 2020

Sig Transduct Target Ther

View full text Add to dashboard Cite

The incidence of lymphoma has gradually increased over previous decades, and it ranks among the ten most prevalent cancers worldwide. With the development of targeted therapeutic strategies, though a subset of lymphoma patients has become curable, the treatment of refractory and relapsed diseases remains challenging. Many efforts have been made to explore new targets and to develop corresponding therapies. In addition to novel antibodies targeting surface antigens and small molecular inhibitors targeting oncogenic signaling pathways and tumor suppressors, immune checkpoint inhibitors and chimeric antigen receptor T-cells have been rapidly developed to target the tumor microenvironment. Although these targeted agents have shown great success in treating lymphoma patients, adverse events should be noted. The selection of the most suitable candidates, optimal dosage, and effective combinations warrant further investigation. In this review, we systematically outlined the advances in targeted therapy for malignant lymphoma, providing a clinical rationale for mechanism-based lymphoma treatment in the era of precision medicine.Signal Transduction and Targeted Therapy (2020) 5:15; https://doi.

show abstract

Section: Cd30mentioning

confidence: 99%

Advances in targeted therapy for malignant lymphoma

Wang

Qin

Huo

et al. 2020

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…CD30, a member of the tumor necrosis factor receptor (TNFR) superfamily, promotes T cell proliferation and cytokine production following TCR stimulation, while also having an opposing role in promoting apoptosis [92]. Expression is limited to a subset of activated lymphocytes found around the follicular regions of lymphoid tissues [93][94][95]. While CD30 is well known for its strong expression in virtually all classical Hodgkin lymphoma, expression of CD30 can also be found on a subset of PTCLs, including ALCL [92][93][94]96].…”

Section: Cd30mentioning

confidence: 99%

“…Expression is limited to a subset of activated lymphocytes found around the follicular regions of lymphoid tissues [93][94][95]. While CD30 is well known for its strong expression in virtually all classical Hodgkin lymphoma, expression of CD30 can also be found on a subset of PTCLs, including ALCL [92][93][94]96]. One study demonstrated that CD30 expression is upregulated during chemotherapy regimens in T-ALL patients.…”

Section: Cd30mentioning

confidence: 99%

Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions

2019

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for the treatment of T cell malignancies. There are many challenges in translating this therapy for T cell disease, including fratricide, T cell aplasia, and product contamination. To the best of our knowledge, no tumor-specific antigen has been identified with universal expression on cancerous T cells, hindering CAR T cell therapy for these malignancies. Numerous approaches have been assessed to address each of these challenges, such as (i) disrupting target antigen expression on CARmodified T cells, (ii) targeting antigens with limited expression on T cells, and (iii) using third party donor cells that are either non-alloreactive or have been genome edited at the T cell receptor α constant (TRAC) locus. In this review, we discuss CAR approaches that have been explored both in preclinical and clinical studies targeting T cell antigens, as well as examine other potential strategies that can be used to successfully translate this therapy for T cell disease.

show abstract

“…Currently, various markers are de ned through immunophenotyping, such as CD5, CD30, BCL2, MYC and TP53 [8,9]. CD5 promotes downstream B-cell receptor signaling, is associated with ABC subtype and more aggressive clinical traits.…”

Section: Introductionmentioning

confidence: 99%

Large-scale transcriptome data analysis reveals prognostic signature genes for overall survival prediction in diffuse large B cell lymphoma

Pan

Yang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND With the improvement of clinical treatment outcomes in Diffuse large B cell lymphoma (DLBCL), the high rate of relapse in DLBCL patients is still an established barrier, due to the therapeutic strategy selection based on potential target remains unsatisfactory. Therefore, there is an urgent need in further exploration of prognostic biomarkers so as to improve the prognosis of DLBCL.METHODS The univariable and multivariable Cox regression models were employed to screen out gene signatures for DLBCL overall survival prediction. The differential expression analysis was used to identify representative genes in high-risk and low-risk groups, respectively, by student t test and fold change. The functional difference between the high-risk and low-risk groups were identified by the gene set enrichment analysis.RESULTS We conducted a systematic data analysis to screen the candidate genes significantly associated with overall survival of DLBCL in three NCBI Gene Expression Omnibus (GEO) datasets. To construct a prognostic model, five genes (CEBPA, CYP27A1, LST1, MREG, and TARP) were then screened and tested using the multivariable Cox model and the stepwise regression method. Kaplan-Meier curve confirmed the good predictive performance of the five-gene Cox model. Thereafter, the prognostic model and the expression levels of the five genes were validated by means of an independent dataset. All five genes were significantly favorable for the prognosis in DLBCL, both in training and validation datasets. Additionally, further analysis revealed the independence and superiority of the prognostic model in risk prediction. Functional enrichment analysis revealed some vital pathways resulting in unfavorable outcome and potential therapeutic targets in DLBCL.CONCLUSION We developed a five-gene Cox model for the clinical outcome prediction of DLBCL patients. Meanwhile, potential drug selection using this model can help clinicians to improve the clinical practice for the patients.

show abstract

Diagnostic, prognostic and therapeutic role of CD30 in lymphoma

Cited by 50 publications

References 84 publications

Advances in targeted therapy for malignant lymphoma

Advances in targeted therapy for malignant lymphoma

Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions

Large-scale transcriptome data analysis reveals prognostic signature genes for overall survival prediction in diffuse large B cell lymphoma

Contact Info

Product

Resources

About